Home Cart Sign in  
Chemical Structure| 775351-61-6 Chemical Structure| 775351-61-6
Chemical Structure| 775351-61-6

Imeglimin HCl

CAS No.: 775351-61-6

Imeglimin HCl is the first in a tetrahydrotriazine-containing class of oral antidiabetic agents, the glimins.

Synonyms: EMD 387008 hydrochloride; Imeglimin hydrochloride

4.5 *For Research Use Only !

Cat. No.: A613391 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇó¶ÊÊ Inquiry Inquiry
5mg ł§Í¶ÊÊ Inquiry Inquiry
10mg łÍò¶ÊÊ Inquiry Inquiry
50mg łÇËó¶ÊÊ Inquiry Inquiry
100mg łËÊǶÊÊ Inquiry Inquiry
250mg ł§Ëî¶ÊÊ Inquiry Inquiry
1g łóóď¶ÊÊ Inquiry Inquiry
5g łËòòʶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÇó¶ÊÊ

  • 5mg

    ł§Í¶ÊÊ

  • 10mg

    łÍò¶ÊÊ

  • 50mg

    łÇËó¶ÊÊ

  • 100mg

    łËÊǶÊÊ

  • 250mg

    ł§Ëî¶ÊÊ

  • 1g

    łóóď¶ÊÊ

  • 5g

    łËòòʶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Imeglimin HCl

CAS No. :775351-61-6
Formula : C6H14ClN5
M.W : 191.66
SMILES Code : [H]Cl.NC1=N[C@@H](C)N=C(N(C)C)N1
Synonyms :
EMD 387008 hydrochloride; Imeglimin hydrochloride
MDL No. :MFCD28167741
InChI Key :UXHLCYMTNMEXKZ-PGMHMLKASA-N
Pubchem ID :54763513

Safety of Imeglimin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.22mL

1.04mL

0.52mL

26.09mL

5.22mL

2.61mL

52.18mL

10.44mL

5.22mL

References

[1]Fouqueray P, Pirags V, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013 Mar;36(3):565-8.

[2]Pirags V, Lebovitz H, et al. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012 Sep;14(9):852-8.

[3]Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021 Mar;23(3):664-673

[4]Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel AL, Fontaine E. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab. 2021 Feb 23;4(2):e00211

[5]Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. Drugs R D. 2015 Sep;15(3):227-32

[6]Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, Bolze S, Shulman GI, Petersen KF, Kibbey RG. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E461-70

[7]Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072

 

Historical Records

Categories